632 related articles for article (PubMed ID: 31197910)
1. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure.
Lu M; Wu KH; Li J; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Daida YG; Schmidt MA; Rupp LB; Zhang T; Trudeau S; Gordon SC
J Viral Hepat; 2019 Oct; 26(10):1210-1217. PubMed ID: 31197910
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
[TBL] [Abstract][Full Text] [Related]
3. Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C.
Morio K; Imamura M; Kawakami Y; Nakamura Y; Hatooka M; Morio R; Fujino H; Nakahara T; Murakami E; Kawaoka T; Tsuge M; Hiramatsu A; Aikata H; Hayes CN; Miki D; Ochi H; Katamura Y; Arataki K; Moriya T; Ito H; Tsuji K; Kohno H; Waki K; Tamura T; Nakamura T; Chayama K;
J Med Virol; 2018 Dec; 90(12):1834-1840. PubMed ID: 30016555
[TBL] [Abstract][Full Text] [Related]
4. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
[TBL] [Abstract][Full Text] [Related]
5. Sofosbuvir-Based Regimens for Chronic Hepatitis C in a Well-Insured U.S. Population: Patient Characteristics, Treatment Adherence, Effectiveness, and Health Care Costs, 2013-2015.
Yin S; Barker L; White JZ; Jiles RB
J Manag Care Spec Pharm; 2019 Feb; 25(2):195-210. PubMed ID: 30698086
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis.
Zheng YX; Ma SJ; Xiong YH; Fan XG
J Gastroenterol Hepatol; 2020 Sep; 35(9):1477-1487. PubMed ID: 32246857
[TBL] [Abstract][Full Text] [Related]
7. Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies.
Darvishian M; Wong S; Binka M; Yu A; Ramji A; Yoshida EM; Wong J; Rossi C; Butt ZA; Bartlett S; Pearce ME; Samji H; Cook D; Alvarez M; Chong M; Tyndall M; Krajden M; Janjua NZ
J Viral Hepat; 2020 Mar; 27(3):243-260. PubMed ID: 31664755
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study.
Gaeta GB; Aghemo A; Menzaghi B; D'Offizi G; Giorgini A; Hasson H; Brancaccio G; Palma M; Termini R;
Medicine (Baltimore); 2018 Jul; 97(27):e11307. PubMed ID: 29979400
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Chronic HCV Infection with the New Direct Acting Antivirals (DAA): First Report of a Real World Experience in Southern Brazil.
Cheinquer H; Sette H; Wolff FH; de Araujo A; Coelho-Borges S; Soares SRP; Barros MFA
Ann Hepatol; 2017; 16(5):727-733. PubMed ID: 28809742
[TBL] [Abstract][Full Text] [Related]
10. High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.
Pellicelli A; Messina V; Giannelli V; Distefano M; Palitti VP; Vignally P; Tarquini P; Izzi A; Moretti A; Babudieri S; Dell'Isola S; Marignani M; Scifo G; Iovinella V; Cariti G; Pompili M; Candilo FD; Fontanella L; Ettorre GM; Vennarecci G; Ippolito AM; Barbarini G
Gut Liver; 2020 May; 14(3):357-367. PubMed ID: 30970444
[TBL] [Abstract][Full Text] [Related]
11. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C.
Di Maio VC; Barbaliscia S; Teti E; Fiorentino G; Milana M; Paolucci S; Pollicino T; Morsica G; Starace M; Bruzzone B; Gennari W; Micheli V; Yu La Rosa K; Foroghi L; Calvaruso V; Lenci I; Polilli E; Babudieri S; Aghemo A; Raimondo G; Sarmati L; Coppola N; Pasquazzi C; Baldanti F; Parruti G; Perno CF; Angelico M; Craxì A; Andreoni M; Ceccherini-Silberstein F;
Liver Int; 2021 Aug; 41(8):1802-1814. PubMed ID: 33497016
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
[TBL] [Abstract][Full Text] [Related]
13. Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.
Papaluca T; Sinclair M; Gow P; Pianko S; Sievert W; Arachchi N; Cameron K; Bowden S; O'Keefe J; Doyle J; Stoove M; Hellard M; Iser D; Thompson A
Liver Int; 2019 Dec; 39(12):2285-2290. PubMed ID: 31355968
[TBL] [Abstract][Full Text] [Related]
14. Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil.
Lobato CMO; Codes L; Silva GF; Souza AFM; Coelho HSM; Pedroso MLA; Parise ER; Lima LMSTB; Borba LA; Evangelista AS; Rezende REF; Cheinquer H; Kuniyoshi ASO; Aires RS; Quintela EHD; Mendes LSC; Nascimento FCV; Medeiros Filho JEM; Ferraz MLCG; Abdala E; Bittencourt PL; ;
Ann Hepatol; 2019; 18(6):849-854. PubMed ID: 31537509
[TBL] [Abstract][Full Text] [Related]
15. High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar.
Hlaing NKT; Nangia G; Tun KT; Lin S; Maung MZ; Myint KT; Kyaw AMM; Maung ST; Sein Win S; Bwa AH; Loza BL; Win KM; Reddy KR
J Viral Hepat; 2019 Oct; 26(10):1186-1199. PubMed ID: 31104344
[TBL] [Abstract][Full Text] [Related]
16. Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis.
Tmu N; Kumar A; Sharma P; Singla V; Bansal N; Arora A
J Clin Exp Hepatol; 2019; 9(1):4-12. PubMed ID: 30765933
[TBL] [Abstract][Full Text] [Related]
17. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW
S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort.
Wong YJ; Thurairajah PH; Kumar R; Tan J; Fock KM; Law NM; Li W; Kwek A; Tan YB; Koh J; Lee ZC; Kumar LS; Teo EK; Ang TL
J Gastroenterol Hepatol; 2021 May; 36(5):1300-1308. PubMed ID: 33217040
[TBL] [Abstract][Full Text] [Related]
19. Ideal oral combinations to eradicate HCV: The role of ribavirin.
Hézode C; Bronowicki JP
J Hepatol; 2016 Jan; 64(1):215-25. PubMed ID: 26409316
[TBL] [Abstract][Full Text] [Related]
20. Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.
Mangia A; Susser S; Piazzolla V; Agostinacchio E; De Stefano G; Palmieri V; Spinzi G; Carraturo I; Potenza D; Losappio R; Arleo A; Miscio M; Santoro R; Sarrazin C; Copetti M
J Hepatol; 2017 Apr; 66(4):711-717. PubMed ID: 27965158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]